Higher vitamin D associated with fewer health problems (37 ng vs 25 ng) – Brazil Nov 2017

Two threshold levels of vitamin D and the prevalence of comorbidities in outpatients of a tertiary hospital.

Osteoporos Int. 2017 Nov 15. doi: 10.1007/s00198-017-4299-2. [Epub ahead of print]
Furuie IN1, Mauro MJJ1, Petruzziello S1, Riechi SC2, Petterle RR3, Boguszewski CL4, Borba VZC5.

Statistically significant differences
in disease rates vs vitamin D level

20-30 ng 30-50 ng
Anemia 6% of patients1% of patients
Arthropathy
(joint disease)
15% 7%
Cardiac disorder 15% 9%
Dyslipidemia
(high cholesterol)
45% 36%
Urinary tract disease 11%5%
Neurological and
psychiatric disorder
20%5%
Glycemic disorder
(Diabetes)
34%26%
Secondary
hyperparathyroidism
8% 0 %
Hypothyroidism 25%34%
Obesity 45%36%
Osteoporosis 34%50%
All others 34%15%
Avg Vit D 25 ng37 ng
Total number
of comorbidities
4.23.4
click here for whole table
click here for whole table


 Download the PDF from SciHub via VitaminDWiki

This study evaluated the number of comorbidities between two normal values of 25OHD in outpatients during 1 year of 25OHD measurements. Five hundred twenty-nine outpatients were included, patients with 25OHD ≥ 20 and < 30 ng/mL had the higher number of comorbidities, suggesting that for this specific population, 25OHD ≥ 30 ng/mL would be more appropriate.

INTRODUCTION : This study evaluated the comorbidities between two values of 25OHD in outpatients of a tertiary hospital.

METHODS: This is a cross-sectional study with measures of 25OHD in 1-year period, excluding 25OHD < 20 and > 50 ng/mL, clinical research participants, and liver disease and chronic renal failure patients. Patients were divided into two groups: group 1 (G1), 25OHD ≥ 20 and < 30 ng/mL; and group 2 (G2), 250HD ≥ 30 and ≤ 50 ng/mL. Medical records were reviewed for demographic, laboratory, and comorbidity data.

RESULTS: From 529 outpatients included, 319 were in G1 (53.3 ± 15.8 years, 85% women), mean 25OHD 24.8 ± 2.8 ng/mL; and 210 outpatients in G2 (56.7 ± 16.0 years, 83% women), mean 25OHD was 36.8 ± 4.8 ng/mL. G1 had the higher number of comorbidities, including altered glycemia, dyslipidemia, hypothyroidism, urinary tract diseases, arthropathy, secondary hyperparathyroidism, anemia, and neurological and psychiatric disorders. Osteoporosis and hypothyroidism were more prevalent in G2. After binary logistic regression, the variables age (OR 0.988, CI 0.97-1.00, p = 0.048), osteoporosis (OR 0.54, CI 0.36-0.80, p = 0.003), dyslipidemia (OR 1.61, CI 1.10-2.39, p = 0.015), arthropathy (OR 2.60, CI 1.40-5.10, p = 0.003), anemia (OR 15.41, CI 3.09-280.08, p = 0.008), and neurological and psychiatric diseases (OR 3.78, CI 1.98-7.88, p = 0.001) maintained significance.

CONCLUSION: Patients with serum 25OHD ≥ 20 and < 30 ng/mL had higher prevalence of comorbidities compared to ≥ 30 ng/mL.

PMID: 29143130 DOI: 10.1007/s00198-017-4299-2

7499 visitors, last modified 17 Nov, 2017,
Printer Friendly Follow this page for updates